Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fuzheng Huayu for Post-COVID-19 Pulmonary Fibrosis
NCT04279197Phase 2Completed
- Sponsor
- Shuguang Hospital
- Start
- Apr 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary fibrosis (PF) comparing FZHY Group with Placebo Group (2 arms). Primary endpoints: The improvement proportion of pulmonary fibrosis judged by HRCT score at 24 weeks and The improvement of lung function (FVC, FEV1, FVC/FEV1) at 24 weeks. Started Apr 2020; status: completed.
02
Drugs
fuzheng huayu
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT04279197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04279197.